▶ 調査レポート

ヒトマイクロバイオームの世界市場分析・規模・シェア・成長・動向・予測:適応症別(胃腸障害・代謝異常、婦人科系疾患、がん)、技術別(16S rRNAシーケンシング、メタゲノムシーケンシング)、治療領域別(胃腸障害、代謝異常、婦人科系疾患、皮膚疾患)

• 英文タイトル:Human Microbiome Market (Indication - Gastrointestinal and Metabolic Disorders, Women’s Health, Cancer; Technology - 16s rRNA Sequencing, Metagenomic Sequencing; Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Women’s Health, Skin Disorders) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Transparency Market Researchが調査・発行した産業分析レポートです。ヒトマイクロバイオームの世界市場分析・規模・シェア・成長・動向・予測:適応症別(胃腸障害・代謝異常、婦人科系疾患、がん)、技術別(16S rRNAシーケンシング、メタゲノムシーケンシング)、治療領域別(胃腸障害、代謝異常、婦人科系疾患、皮膚疾患) / Human Microbiome Market (Indication - Gastrointestinal and Metabolic Disorders, Women’s Health, Cancer; Technology - 16s rRNA Sequencing, Metagenomic Sequencing; Therapeutic Area - Gastrointestinal Disorders, Metabolic Disorders, Women’s Health, Skin Disorders) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026 / TPM-B06019資料のイメージです。• レポートコード:TPM-B06019
• 出版社/出版日:Transparency Market Research / 2018年5月31日
• レポート形態:英文、PDF、176ページ
• 納品方法:Eメール
• 産業分類:医療・バイオ
• 販売価格(消費税別)
  Single User¥631,655 (USD5,795)▷ お問い合わせ
  Multi User¥958,655 (USD8,795)▷ お問い合わせ
  Global Site License¥1,285,655 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、ヒトマイクロバイオームの世界市場について調べ、ヒトマイクロバイオームの世界規模、市場動向、市場環境、適応症別(胃腸障害・代謝異常、婦人科系疾患、がん)分析、技術別(16S rRNAシーケンシング、メタゲノムシーケンシング)分析、治療領域別(胃腸障害、代謝異常、婦人科系疾患、皮膚疾患)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。
・序文・調査範囲・調査手法
・エグゼクティブサマリー
・ヒトマイクロバイオームの世界市場動向
・ヒトマイクロバイオームの世界市場環境
・ヒトマイクロバイオームの世界市場規模
・ヒトマイクロバイオームの世界市場規模:適応症別(胃腸障害・代謝異常、婦人科系疾患、がん)
・ヒトマイクロバイオームの世界市場規模:技術別(16S rRNAシーケンシング、メタゲノムシーケンシング)
・ヒトマイクロバイオームの世界市場規模:治療領域別(胃腸障害、代謝異常、婦人科系疾患、皮膚疾患)
・ヒトマイクロバイオームの世界市場:地域別市場規模・分析
・ヒトマイクロバイオームの北米市場規模・予測
・ヒトマイクロバイオームのアメリカ市場規模・予測
・ヒトマイクロバイオームの中南米市場規模・予測
・ヒトマイクロバイオームのヨーロッパ市場規模・予測
・ヒトマイクロバイオームのアジア市場規模・予測
・ヒトマイクロバイオームの日本市場規模・予測
・ヒトマイクロバイオームの中国市場規模・予測
・ヒトマイクロバイオームの中東市場規模・予測
・ヒトマイクロバイオームのアフリカ市場規模・予測
・競争状況・関連企業情報

Human Microbiome Market – Overview

Human microbiome, also known as microbiota, includes microbes such as fungi, bacteria, and virus. These microbes reside in oral mucosa, saliva, gastrointestinal tracts, conjunctiva, or on the surface or in deep layers of the skin. At present, extensive research is being conducted to discover the importance of these micro-organisms in maintaining immune systems and their contribution in digestion of food. Large number of microbes reside in the large intestine, with region of the human body having a distinct community of microbes dwelling. Studies are still in progress to understand factors regulating microbial colonization in the body that are just millimeters apart. The human microbiome project (HMP) was launched in 2008 as a U.S. National Institute of Health. This was initiated to identify and characterize microbes found in the healthy and diseases human body.

This report on the global human microbiome market analyzes the future prospects of the market. The market for diagnostics and therapeutics is independently analyzed as two separate markets within the report. The market for human microbiome therapeutics is segmented based on therapeutic area and region, while the market for human microbiome diagnostics is segmented in terms of indication, technology, and region. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. A detailed qualitative analysis of factors driving and restraining the market and opportunities is provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2018 and 2026 for diagnostics and 2020 to 2026 for therapeutics, along with the compound annual growth rate (CAGR %) from 2018/2020 to 2026 are provided for all the segments. Market related factors such as estimated launch of products, drugs in the pipeline, and industry-institute collaborations in research have been taken into consideration while estimating the market size. Growth rate for each segment within the global human microbiome market has been determined after a thorough analysis of past and present trends, demographics, future trends, technological developments, clinical trials, and regulatory requirements. These factors are projected to help market players to take strategic decisions to strengthen their positions and increase share in the global market.

Based on indication, the global human microbiome diagnostics market has been segmented into gastrointestinal and metabolic disorders, women’s health, cancer, and others. The gastrointestinal & metabolic disorders segment is projected to expand at a considerable pace due to high unmet medical needs for gut health disorders and rise in population suffering from lifestyle-based metabolic diseases. In terms of technology, the market has been bifurcated into 16s rRNA sequencing and metagenomic sequencing. Both these forms have been documented to have various advantages and provide accurate testing and hence, these are likely to garner nearly equal share of the overall diagnostics market during the forecast period. Based on therapeutic area, the market has been segmented into gastrointestinal disorders, metabolic disorders, women’s health, skin disorders, and others. The others segment includes autoimmune disorders, infant health disorders, and rare diseases.

In terms of region, the global human microbiome market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Additionally, the regions have been further segmented by major countries. These include the U.S., Canada, the U.K., Germany, China, Japan, Brazil, Mexico, the UAE, and South Africa. The competition landscape section included in the report is likely to assist existing players increase their market shares and new companies to establish their presence in the human microbiome market. The report profiles major players operating in the human microbiome market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include AOBiome LLC, Osel, Inc., Seres Therapeutics, Second Genome, uBiome, Inc., Metabiomics Corp., Rebiotix, Inc., and Vedanta Biosciences.

The global human microbiome market has been segmented as follows:

Global Human Microbiome Diagnostics Market, by Indication

Gastrointestinal and Metabolic Disorders
Women’s Health
Cancer
Others
Global Human Microbiome Diagnostics Market, by Technology

16s rRNA Sequencing
Metagenomic Sequencing
Global Human Microbiome Therapeutics Market, by Therapeutic Area

Gastrointestinal Disorders
Metabolic Disorders
Women’s Health
Skin Disorders
Others
Global Human Microbiome Diagnostics and Therapeutics Market, by Geography

North America
U.S.
Canada
Europe
Germany
U.K.
Rest of Europe
Asia Pacific
China
Japan
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
South Africa
Rest of Middle East & Africa

レポート目次

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Human Microbiome Market

4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Developments
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Porters Five Forces Analysis
4.4. Global Human Microbiome Market Analysis and Forecasts
4.4.1. Global Human Microbiome Diagnostics Market Analysis and Forecast, 2018–2026
4.4.2. Global Human Microbiome Therapeutics Market Analysis and Forecast, 2020–2026
4.5. Global Human Microbiome Market Outlook
4.6. Human Microbiome Therapeutics: Pipeline Overview
4.7. Regulatory Scenario
4.8. Impact of human microbiome therapeutics on current treatment options
4.9. Key Mergers and Acquisitions

5. Global Human Microbiome Diagnostics Market Analysis and Forecasts, by Indication
5.1. Key Findings
5.2. Introduction
5.3. Market Size (US$ Mn) Forecast, by Indication
5.3.1. Gastrointestinal and Metabolic Disorders
5.3.2. Women’s Health
5.3.3. Cancer
5.3.4. Others
5.4. Market Attractiveness Analysis, by Indication, 2018
5.5. Key Trends

6. Global Human Microbiome Diagnostics Market Analysis and Forecasts, by Technology
6.1. Introduction
6.2. Market Size (US$ Mn) Forecast, by Technology
6.2.1. 16s rRNA Sequencing
6.2.2. Metagenomic Sequencing
6.3. Market Attractiveness Analysis, by Technology, 2018
6.4. Key Developments

7. Global Human Microbiome Therapeutics Market Analysis and Forecasts, by Therapeutic Area
7.1. Key Findings
7.2. Introduction
7.3. Market Size (US$ Mn) Forecast, by Therapeutic Area
7.3.1. Gastrointestinal Disorders
7.3.2. Metabolic Disorders
7.3.3. Women’s Health
7.3.4. Skin Disorders
7.3.5. Others
7.4. Market Attractiveness Analysis, by Therapeutic Area, 2020
7.5. Key Trends

8. Global Human Microbiome Market Analysis and Forecasts, by Region
8.1. Introduction
8.2. Market Size (US$ Mn) Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region,
8.3.1. Global Human Microbiome Diagnostics Market (2018)
8.3.2. Global Human Microbiome Therapeutics Market (2020)

9. North America Human Microbiome Market Analysis and Forecast
9.1. Introduction
9.2. Market Size (US$ Mn) Forecast, by Indication
9.2.1. Gastrointestinal and Metabolic Disorders
9.2.2. Women’s Health
9.2.3. Cancer
9.2.4. Others
9.3. Market Size (US$ Mn) Forecast, by Technology
9.3.1. 16s rRNA Sequencing
9.3.2. Metagenomic Sequencing
9.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
9.4.1. Gastrointestinal Disorders
9.4.2. Metabolic Disorders
9.4.3. Women’s Health
9.4.4. Skin Disorders
9.4.5. Others
9.5. Market Size (US$ Mn) Forecast, by Country
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis, by Indication, 2018
9.7. Market Attractiveness Analysis, by Technology, 2018
9.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
9.9. Key Trends

10. Europe Human Microbiome Market Analysis and Forecast
10.1. Introduction
10.2. Market Size (US$ Mn) Forecast, by Indication
10.2.1. Gastrointestinal and Metabolic Disorders
10.2.2. Women’s Health
10.2.3. Cancer
10.2.4. Others
10.3. Market Size (US$ Mn) Forecast, by Technology
10.3.1. 16s rRNA Sequencing
10.3.2. Metagenomic Sequencing
10.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
10.4.1. Gastrointestinal Disorders
10.4.2. Metabolic Disorders
10.4.3. Women’s Health
10.4.4. Skin Disorders
10.4.5. Others
10.5. Market Size (US$ Mn) Forecast, by Country
10.5.1. U.K.
10.5.2. Germany
10.5.3. Rest of Europe
10.6. Market Attractiveness Analysis, by Indication, 2018
10.7. Market Attractiveness Analysis, by Technology, 2018
10.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
10.9. Key Trends

11. Asia Pacific Human Microbiome Market Analysis and Forecast
11.1. Introduction
11.2. Market Size (US$ Mn) Forecast, by Indication
11.2.1. Gastrointestinal and Metabolic Disorders
11.2.2. Women’s Health
11.2.3. Cancer
11.2.4. Others
11.3. Market Size (US$ Mn) Forecast, by Technology
11.3.1. 16s rRNA Sequencing
11.3.2. Metagenomic Sequencing
11.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
11.4.1. Gastrointestinal Disorders
11.4.2. Metabolic Disorders
11.4.3. Women’s Health
11.4.4. Skin Disorders
11.4.5. Others
11.5. Market Size (US$ Mn) Forecast, by Country
11.5.1. China
11.5.2. Japan
11.5.3. Rest of Asia Pacific
11.6. Market Attractiveness Analysis, by Indication, 2018
11.7. Market Attractiveness Analysis, by Technology, 2018
11.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
11.9. Key Trends

12. Latin America Human Microbiome Market Analysis and Forecast
12.1. Introduction
12.2. Market Size (US$ Mn) Forecast, by Indication
12.2.1. Gastrointestinal and Metabolic Disorders
12.2.2. Women’s Health
12.2.3. Cancer
12.2.4. Others
12.3. Market Size (US$ Mn) Forecast, by Technology
12.3.1. 16s rRNA Sequencing
12.3.2. Metagenomic Sequencing
12.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
12.4.1. Gastrointestinal Disorders
12.4.2. Metabolic Disorders
12.4.3. Women’s Health
12.4.4. Skin Disorders
12.4.5. Others
12.5. Market Size (US$ Mn) Forecast, by Country
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis, by Indication, 2018
12.7. Market Attractiveness Analysis, by Technology, 2018
12.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
12.9. Key Trends

13. Middle East & Africa Human Microbiome Market Analysis and Forecast
13.1. Introduction
13.2. Market Size (US$ Mn) Forecast, by Indication
13.2.1. Gastrointestinal and Metabolic Disorders
13.2.2. Women’s Health
13.2.3. Cancer
13.2.4. Others
13.3. Market Size (US$ Mn) Forecast, by Technology
13.3.1. 16s rRNA Sequencing
13.3.2. Metagenomic Sequencing
13.4. Market Size (US$ Mn) Forecast, by Therapeutic Area
13.4.1. Gastrointestinal Disorders
13.4.2. Metabolic Disorders
13.4.3. Women’s Health
13.4.4. Skin Disorders
13.4.5. Others
13.5. Market Size (US$ Mn) Forecast, by Country
13.5.1. UAE
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis, by Indication, 2018
13.7. Market Attractiveness Analysis, by Technology, 2018
13.8. Market Attractiveness Analysis, by Therapeutic Area, 2020
13.9. Key Trends

14. Competition Landscape
14.1. Company Profiles
14.1.1. AO Biome LLC
14.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.1.2. Recent Developments
14.1.1.3. Product Portfolio
14.1.1.4. SWOT Analysis
14.1.1.5. Strategic Overview
14.1.2. Enterome Biosciences SA
14.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.2.2. Product Portfolio
14.1.2.3. SWOT Analysis
14.1.2.4. Strategic Overview
14.1.3. Metabiomics Corp.
14.1.3.1. Company Overview (HQ, business segments, employee strength)
14.1.3.2. Product Portfolio
14.1.3.3. SWOT Analysis
14.1.3.4. Recent Developments
14.1.3.5. Strategic Overview
14.1.4. MicroBiome Therapeutics LLC
14.1.4.1. Company Overview (HQ, business segments, employee strength)
14.1.4.2. Product Portfolio
14.1.4.3. SWOT Analysis
14.1.4.4. Strategic Overview
14.1.4.5. Recent Developments
14.1.5. Osel, Inc.
14.1.5.1. Company Overview (HQ, business segments, employee strength)
14.1.5.2. Clinical Trial Candidates
14.1.5.3. Product Portfolio
14.1.5.4. SWOT Analysis
14.1.5.5. Strategic Overview
14.1.6. Rebiotix, Inc.
14.1.6.1. Company Overview (HQ, business segments, employee strength)
14.1.6.2. Product Portfolio
14.1.6.3. SWOT Analysis
14.1.6.4. Recent Developments
14.1.6.5. Strategic Overview
14.1.7. uBiome, Inc.
14.1.7.1. Company Overview (HQ, business segments, employee strength)
14.1.7.2. Recent Developments
14.1.7.3. Product Portfolio
14.1.7.4. SWOT Analysis
14.1.7.5. Strategic Overview
14.1.8. Second Genome
14.1.8.1. Company Overview (HQ, business segments, employee strength)
14.1.8.2. Financial Overview: Funding and Investments
14.1.8.3. Product Portfolio
14.1.8.4. SWOT Analysis
14.1.8.5. Strategic Overview
14.1.9. Seres Therapeutics
14.1.9.1. Company Overview (HQ, business segments, employee strength)
14.1.9.2. Product Portfolio
14.1.9.3. Financial Overview
14.1.9.4. SWOT Analysis
14.1.9.5. Strategic Overview
14.1.10. Synthetic Biologics, Inc.
14.1.10.1. Company Overview (HQ, business segments, employee strength)
14.1.10.2. Product Portfolio
14.1.10.3. Financial Overview
14.1.10.4. SWOT Analysis
14.1.10.5. Strategic Overview
14.1.11. Vedanta Biosciences
14.1.11.1. Company Overview (HQ, business segments, employee strength)
14.1.11.2. Product Portfolio
14.1.11.3. Recent Developments
14.1.11.4. SWOT Analysis
14.1.11.5. Strategic Overview
14.1.12. Others
14.1.12.1. Metabogen AB
14.1.12.2. Becton Dickinson & Company
14.1.12.3. Evelo Biosciences
14.1.12.4. ARTPred
14.1.12.5. MaaT Pharma
14.1.12.6. Blue Turtle Bio Technologies
14.1.12.7. Axial Therapeutics
14.1.12.8. Whole Biome
14.1.12.9. 4D Pharma
14.1.12.10. Symbiotix Therapies
14.1.12.11. Phi Therapeutics
14.1.12.12. Synlogic
14.1.12.13. Biospherex LLC

List of Tables

Table 1: Key Mergers and Acquisitions
Table 2: Global Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 3: Global Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 2018–2026
Table 4: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2026
Table 5: Global Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Region
Table 6: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Region
Table 7: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 8: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 2018–2026
Table 9: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country, 2018–2026
Table 10: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2026
Table 11: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020–2026
Table 12: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 13: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 2018–2026
Table 14: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Country, 2018–2026
Table 15: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2026
Table 16: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020–2026
Table 17: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 18: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 2018–2026
Table 19: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Country, 2018–2026
Table 20: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2026
Table 21: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020–2026
Table 22: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 23: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 2018–2026
Table 24: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country, 2018–2026
Table 25: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2026
Table 26: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020–2026
Table 27: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 2018–2026
Table 28: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 2018–2026
Table 29: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country, 2018–2026
Table 30: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2026
Table 31: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020–2026